GreenHouse Holdings, Inc. (OTCQB:GRHU), announced that it has been engaged to utilize Southern California Edison’s (SCE) Automated Demand Response (Auto-DR) program in Gulfstream Aerospace Corporation’s Long Beach, CA facility. GreenHouse is a qualified service provider of SCE’s Auto-DR program, providing site assessment, feasibility studies, project development, engineering, and installation of enabling technologies and complete processing of all incentives.
The Auto-DR program offers significant financial incentives and technical support to SCE customers with automated load control systems that participate in demand response events. Auto-DR uses control systems to automatically achieve specified energy demand reductions (kW and duration) during periods of peak energy consumption. In utilizing the Auto-DR system, Gulfstream will reduce electric consumption during costly peak energy periods when the demand is highest. Additionally, the system provides Gulfstream the ability to reduce operating costs by curtailing the use and purchase of electricity. Gulfstream will then receive financial incentives from SCE.
“Auto-DR is just one of the innovative services Greenhouse offers to help our clients reduce energy consumption by deploying state-of-the-art technology,” says Rob Davis, Vice President of GreenHouse Holdings, Inc. “We are truly honored to be selected by Gulfstream and we are looking forward to the Auto-DR project as the first of many services offered in support of Gulfstream’s corporate energy stewardship initiatives. This project goes to the heart of Greenhouse’s mission to deliver sustainable solutions that reduce energy consumption with a positive return on investment.”
GreenHouse Holdings, Inc. is a leading provider of energy efficiency solutions and sustainable infrastructure products. The company designs, engineers and installs disparate products and technologies with visible return on investment, enabling our clients to reduce their energy costs. Our target markets for our energy efficiency solutions include residential, commercial and industrial, as well as government and military markets.
Virgin Media, Inc. (Nasdaq:VMED) announced on December 09, 2010, the repurchase of 500,000 shares of common stock on 8 December 2010 as a part of the �700 million capital return program previously announced on 28 July 2010. The highest price paid per share was $27.24 and the lowest price paid per share was $26.89. The repurchased shares will be cancelled. As of 8 December 2010, after giving effect to the cancellation of these shares, the number of shares of common stock issued and outstanding would be 321,941,267.
Virgin Media Inc., through its subsidiaries, provides of entertainment and communications services in the United Kingdom. The company operates through three segments: Consumer, Business, and Content. The Consumer segment offers cable broadband Internet, television, and fixed line telephone services under the Virgin Media brand to residential customers; mobile telephony services through Virgin Mobile, a mobile virtual network operator; and broadband and telephone services to residential customers through third-party telecommunications networks.
Patterson-UTI Energy Inc. (Nasdaq:PTEN) reported that for the month of November 2010, the Company had an average of 193 drilling rigs operating, including 182 rigs in the United States and 11 rigs in Canada. For the two months ended November 2010, the Company had an average of 193 drilling rigs operating, including 181 rigs in the United States and 12 rigs in Canada.
Patterson-UTI Energy, Inc. provides onshore contract drilling services to independent oil and natural gas operators in North America. It offers pressure pumping services, including well stimulation and cementing for completion of new wells, and remedial work on existing wells to oil and natural gas operators primarily in the Appalachian Basin. The company provides contract drilling services principally in Texas, New Mexico, Oklahoma, Arkansas, Louisiana, Mississippi, Colorado, Utah, Wyoming, Montana.
Human Genome Sciences Inc. (Nasdaq:HGSI) and GlaxoSmithKline PLC (GSK) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of the Biologics License Application (BLA) for BENLYSTA� (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from December 9, 2010 to March 10, 2011. After the FDA Arthritis Advisory Committee met on November 16, 2010 to consider the BENLYSTA BLA, the FDA requested some additional information from HGS, which has been submitted.
Human Genome Sciences Inc. operates as a biopharmaceutical company in the United States. The company’s clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of BENLYSTA for systemic lupus erythematosus; ZALBIN for chronic hepatitis C; and raxibacumab for inhalation anthrax. Its oncology products include Mapatumumab (HGS-ETR1), a Phase II product for the treatment of non-small cell lung cancer.